comparemela.com

Latest Breaking News On - Maria de miguel - Page 1 : comparemela.com

Backing Sustainability, Digital Health, Future Work Trends

Backing Sustainability, Digital Health, Future Work Trends
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Supporting sustainability, digital health, and the future of work

The MIT and Accenture Convergence Initiative for Industry and Technology will support three new research projects led by MIT faculty members Jessika Trancik, Anette "Peko" Hosoi, and Thomas Malone.

Transgene Confirms the Potential of the Intravenous Route of its Invir IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene Confirms the Potential of the Intravenous Route of its Invir IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

Press release content from Business Wire. The AP news staff was not involved in its creation. Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses April 9, 2021 GMT Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas. These data provide a clinical proof of concept for Transgene’s double deleted VV cop TK - RR - patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.